Protecting Renal Function in Chronic Kidney Disease Patients with Isolated Nighttime Hypertension

NANot yet recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 30, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Chronic Kidney Disease(CKD)Nocturnal Hypertension
Interventions
DRUG

Antihypertensive treatment with Arotinolol or Amlodipine or Clonidine

Participants will receive Almar 10 mg orally once daily between 8:00 PM and midnight. At the subsequent visit, if nocturnal blood pressure remains above the target of \<120/70 mmHg, Amlodipine Besylate will be added at a dose of 2.5 mg to 5 mg orally once daily. Should nocturnal blood pressure still not achieve the target at the following visit, Clonidine Hydrochloride 75 µg will be added to the regimen. The target for nocturnal blood pressure control is set at \<120/70 mmHg. For participants whose clinic blood pressure exceeds 140/90 mmHg, an unscheduled visit will be arranged within one month. If elevated clinic blood pressure persists during this visit, a 24-hour Ambulatory Blood Pressure Monitoring (ABPM) will be conducted. If the ABPM results indicate daytime blood pressure ≥135/85 mmHg, open-label add-on antihypertensive therapy will be initiated, prioritizing the use of antihypertensive medications outside of the study drugs to achieve blood pressure control.

DRUG

Placebo-controlled group

Participants are treated with corresponding placebo

All Listed Sponsors
lead

Shanghai Institute of Hypertension

OTHER

NCT06780865 - Protecting Renal Function in Chronic Kidney Disease Patients with Isolated Nighttime Hypertension | Biotech Hunter | Biotech Hunter